AMSBIO Launches Animal-Free and Endotoxin-Free Stem Cell Factors
A new range of animal-free and endotoxin-free growth factors and cytokines, tailored to stem cell research, has been launched by AMSBIO — a leading supplier of recombinant proteins.
The success of stem cell research depends on the development of optimal cell culture systems. Both expansion and differentiation of stem cells is highly reliant on growth factor and cytokine supplements, with the activity and purity of these recombinants being critical to successful research and clinical applications. Despite recognised limitations, E. coli and mammalian cells remain the dominant expression systems for commercial recombinant protein production. Although significant improvements in manufacture have been made, both systems present a risk of unwanted contamination from pathogens and endotoxins.
Endotoxins are an unavoidable by-product of commercial E.coli recombinant protein manufacture, including those produced for stem cell research. The stability of endotoxins and affinity for proteins make it almost impossible to completely remove endotoxins. As a result the currently accepted safety limit of endotoxin impurities in recombinant protein products is below < 0.1 ng/µg endotoxin or 1 EU/mg. Although pathogen risks are well documented, there are a growing number of reports that demonstrate endotoxin concentrations as low as 2 pg/mL can result in significant biological responses.
To address the growing body of evidence suggesting accepted levels of endotoxin contamination may significantly compromise stem cell maintenance and differentiation, AMSBIO has launched its new range of animal-free and endotoxin-free growth factors and cytokines. These new recombinant growth factors and cytokines are produced in a plant based expression system that utilises barley seed to eliminate the risks and limitations associated with these traditional expression systems.
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance